Ikena Oncology, Inc. (IKNA)

NASDAQ: IKNA · IEX Real-Time Price · USD
11.37
0.38 (3.46%)
At close: Jan 14, 2022 4:00 PM
11.00
-0.37 (-3.25%)
After-hours:Jan 14, 2022 4:02 PM EST
Market Cap478.93M
Revenue (ttm)10.83M
Net Income (ttm)-62.96M
Shares Out42.12M
EPS (ttm)-3.19
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume53,494
Open10.68
Previous Close10.99
Day's Range10.68 - 11.37
52-Week Range9.63 - 37.61
Betan/a
AnalystsStrong Buy
Price Target26.33 (+131.6%)
Earnings DateNov 11, 2021

About IKNA

Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degradi...

IndustryBiotechnology
IPO DateMar 26, 2021
Employees58
Stock ExchangeNASDAQ
Ticker SymbolIKNA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for Ikena Oncology stock is "Strong Buy." The 12-month stock price forecast is 26.33, which is an increase of 131.57% from the latest price.

Price Target
$26.33
(131.57% upside)
Analyst Consensus: Strong Buy

News

Ikena Appoints Michelle Zhang, Ph.D., Industry and Company Veteran, as Chief Scientific Officer

Dr. Zhang steps into the CSO role after spending more than five years at Ikena in research and development leadership

1 month ago - GlobeNewsWire

Ikena Oncology Presents Data at SITC 36th Annual Meeting Describing the Indication Selection Methodology, Translation...

Data supports and describes the ongoing Phase 1a/b clinical trial of IK-175 as a single agent and in combination with nivolumab in advanced solid tumors

2 months ago - GlobeNewsWire

Ikena Oncology Reports Third Quarter 2021 Financial Results and Corporate Update

IND for IK-930 accepted by FDA; Phase 1 clinical trial expected to initiate in early 2022

2 months ago - GlobeNewsWire

Ikena Oncology to Participate in November 2021 Virtual Investor Conferences

BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that ma...

2 months ago - GlobeNewsWire

Ikena Oncology Announces FDA Acceptance of IND Application of Novel TEAD Inhibitor IK-930

Ikena expects to initiate its first-in-human phase 1 clinical trial in early 2022 in patients with solid tumors that harbor genetic alterations across the Hippo pathway Ikena expects to initiate its fir...

2 months ago - GlobeNewsWire

Ikena Oncology Presents Data at AACR-NCI-EORTC Virtual Conference Demonstrating Potential of TEAD Inhibitors in Cance...

BOSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that th...

3 months ago - GlobeNewsWire

Ikena Oncology to Present a Trial-in-Progress Update, Translational Data, and Indication Selection Methodology for No...

BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that three abstr...

3 months ago - GlobeNewsWire

Ikena Oncology to Participate in September 2021 Virtual Investor Conferences

BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways, today announced...

4 months ago - GlobeNewsWire

Ikena Oncology to Participate in Targeted Oncology Panel at the William Blair Biotech Focus Conference 2021

BOSTON, July 08, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation and s...

6 months ago - GlobeNewsWire

Ikena Oncology to Participate in the 2021 Jefferies Virtual Healthcare Conference

BOSTON--(BUSINESS WIRE)--Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation and spread of cancer, ...

7 months ago - Business Wire

Ikena Oncology Reports First Quarter 2021 Financial Results and Outlines Key Corporate Objectives for 2021

BOSTON--(BUSINESS WIRE)--Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation and spread of cancer, ...

8 months ago - Business Wire

Ikena Oncology Appoints Dr. Maria Koehler to its Board of Directors

BOSTON--(BUSINESS WIRE)--Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and s...

9 months ago - Business Wire

Why Ikena Oncology, Evelo Biosciences And 180 Life Sciences Are Rallying Today

Ikena Oncology, Inc. (NASDAQ: IKNA), 180 Life Sciences Corp. (NASDAQ: ATNF) and Evelo Biosciences, Inc. (NASDAQ: EVLO) are among the major biopharma movers of Monday. Ikena Oncology Gains On Fund Buying...

Other symbols:ATNFEVLO
9 months ago - Benzinga

Ikena Oncology Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purch...

BOSTON--(BUSINESS WIRE)--Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and s...

9 months ago - Business Wire

Ikena Oncology Announces Pricing of Initial Public Offering

BOSTON--(BUSINESS WIRE)--Ikena Oncology, Inc. (“Ikena”), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer...

9 months ago - Business Wire